Marketing: Page 2
-
New AMA policies target GLP-1 coverage, corporate medicine
The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.
By Susanna Vogel • Nov. 14, 2023 -
Obesity drugs
Wegovy study details revive debate over GLP-1 impact on devices
Shares in several heart device makers, which have been battered over the perceived impact of obesity medicines, rose this week following AHA data on Novo’s therapy.
By Susan Kelly • Nov. 13, 2023 -
Trendline
Commercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Biogen, Sage set price of postpartum depression pill at $15,900
The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.
By Ned Pagliarulo • Nov. 7, 2023 -
Sponsored by Viatris
Transforming MS care to meet patient needs
Developing holistic treatment approaches that address patient needs today and in the future.
By Abhijit Barve, MD, PhD, MBA, Chief Medical Officer, Viatris • Nov. 6, 2023 -
Obesity drugs
Novo, Lilly buoyed by fast-growing GLP-1 drug sales
The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.
By Jonathan Gardner • Nov. 2, 2023 -
Obesity drugs
The obesity drug effect: What medical device executives are saying
Stock selloffs across the medical device sector have erased hundreds of billions of dollars in market value. But medtech executives argue GLP-1 drug demand will complement, not cannibalize, their sales.
By Susan Kelly • Nov. 2, 2023 -
RSV vaccines
GSK outpaces Pfizer in RSV vaccine market
Sales of GSK’s new RSV shot Arexvy were more than double what Pfizer reported for its rival product, suggesting substantial demand this fall.
By Kristin Jensen • Nov. 1, 2023 -
Sponsored by Veeva
5 things to look for in a marketing analytics partner
Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.
Oct. 23, 2023 -
Roche eye drug sales grow as Regeneron plays catch-up
The Swiss pharma reported expanding U.S. market share for its new AMD drug Vabysmo as Regeneron tries to rebound from a now-resolved delay for its high-dose Eylea.
By Jonathan Gardner • Oct. 19, 2023 -
Keytruda gains first approval for pre- and post-surgery use in lung cancer
The Merck drug leads competitors Opdivo and Imfinzi into a new immunotherapy setting, which aims to improve outcomes following the surgical removal of tumors.
By Jonathan Gardner • Oct. 17, 2023 -
Pfizer wins FDA approval for its $7B colitis drug
Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.
By Jonathan Gardner • Oct. 13, 2023 -
ALS drug development
Amylyx’s ALS drug knocked back again in Europe
Following a re-examination, the EMA again concluded that Albrioza — known as Relyvrio in the U.S. — should not be cleared for the European market.
By Jacob Bell • Oct. 13, 2023 -
Obesity drugs
GLP-1 drug demand leaves employers in a bind over coverage
Employers face a difficult decision over whether to cover the popular weight loss therapies, which cost between $900 and $1,400 for a typical month’s supply at list price.
By Rebecca Pifer • Oct. 13, 2023 -
Apellis sales numbers show steady demand for new eye drug, despite safety worries
The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.
By Kristin Jensen • Oct. 5, 2023 -
Sponsored by Cognizant
Using AI to create an end-to-end customer experience in pharma
Silos abound in the pharma world, especially when it comes to customer care and call center support. Using AI can change everything, though. Here’s how.
Oct. 2, 2023 -
New Alzheimer's drugs
Eisai’s Alzheimer’s drug Leqembi approved in Japan
Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.
By Ned Pagliarulo • Sept. 25, 2023 -
New RSV vaccines can be powerful tools, but rollout poses test
Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID-19 and flu.
By Delilah Alvarado • Sept. 18, 2023 -
FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet
The drug, known scientifically as momelotinib, is now cleared to treat myelofibrosis and will compete against rival medicines sold by Incyte and Bristol Myers Squibb.
By Jacob Bell • Sept. 18, 2023 -
J&J to phase out Janssen name in corporate rebrand
Janssen will be recast as Johnson & Johnson Innovative Medicine, melding the drugs division’s identity more closely with its parent.
By Ned Pagliarulo • Sept. 15, 2023 -
Insulin pump-makers grapple with questions about GLP-1s
New weight loss drugs have sparked a stock selloff for some device makers, but medtech analysts don’t see them a likely to undermine the companies’ business — yet.
By Elise Reuter • Sept. 14, 2023 -
Akili cuts 40% of workforce, plans shift to non-prescription model
The digital therapeutics company expects to extend its cash runway into 2025 with the changes.
By Elise Reuter • Sept. 13, 2023 -
CDC endorses new COVID boosters as focus turns to rollout
This fall will now feature vaccination campaigns for COVID-19, influenza and respiratory syncytial virus.
By Delilah Alvarado • Sept. 13, 2023 -
Sponsored by Alexander Group
Do not miss the return to growth
The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.
By Alexander Group • Sept. 5, 2023 -
FTC allows Amgen’s $28B deal for Horizon to go through, with conditions
The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.
By Jonathan Gardner • Sept. 1, 2023 -
FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon
Urged by a judge, the antitrust regulator said it wants to start discussions “regarding the proper resolution of this matter” — a potential prelude to a settlement.
By Jonathan Gardner • Aug. 28, 2023